Taro Pharmaceutical Industries confirmed that it had received a letter on 19 October 2011 from Sun Pharma offering to buy all outstanding shares of Taro, not currently held by Sun Pharma, at a price of US$24.50 per share.
Sun Pharma offers to buy remaining Taro shares
Home/Pharma News
|
Posted 10/11/2011
0
Post your comment

The letter from Sun Pharma states, in part, that the proposal represents a valuation of approximately US$1.09 billion for Taro and the proposed purchase price represents a 25.96% premium over Taro’s closing price (US$19.45) on 17 October 2011.
India-based generics manufacturer Sun Pharma only managed to gain a controlling stake in Israel’s Taro in September 2010 after a prolonged legal battle [1], and currently holds 66% of Taro’s shares.
However, not all Taro shareholders are happy with the offer. Grand Slam Asset Management (Grand Slam), which holds some of Taro’s remaining shares, stated in a letter to Taro that they believed that the offer did not ‘fairly value’ the Taro shares. They believe that a fair value would be at least US$48.50 per share, which is almost double what Sun Pharma has offered.
Grand Slam stated in its letter that a fair evaluation would be at least 15 times the company’s earnings before interest taxes depreciation and amortisation (EBITDA). This they have based on data from six similar acquisitions of US generic drug companies.
Grand Slam has urged the Board of Directors of Taro to hire an independent counsel and investment bankers to ensure a fair offer from Sun Pharma or to conduct an unbiased auction of Taro.
An independent committee of Taro’s Board of Directors is expected to review the offer from Sun Pharma’s in due course.
Related articles
Sun Pharma’s US operations partially on track
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Sun Pharma finally wins battle for Taro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 November 10]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-finally-wins-battle-for-Taro
Source: Reuters, Taro
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment